Loading...
For Investors 2017-05-03T17:02:22+00:00

Have you read about our work yet?

Read the layman explanation of our technologies

Read the technical explanation of our technologies

Why invest?

  • Two development paths: platform technology with the ability to be licensed by others and proprietary therapeutic product development
  • A major step to standardize and simplify a promising approach to cancer therapy that homes in on cancer cells thereby avoiding the nasty side effects of traditional chemotherapeutics
  • Current and future partnerships could lead to early licensing revenue opportunities
  • Potential acquisition target

Download detailed investor information

Corporate information

We are a reporting company in Canada and file with the Canadian Securities Administrators our annual reports with annual financial statements, interim reports, management information, circulars (proxy statements), press releases, and other items, which are publicly available on SEDAR.

Contact investor relations

To speak to our investor relations representative, please contact Babak Pedram at 416-644-5081.

CUSIP:
007628

Year End:
July 31

Shares Issued and Outstanding:
As of April 1, 2016 – 112,880,418

Transfer Agent:
Computershare Investor Services Inc.

Officers and Directors:
Randal Chase, Ph.D.
CEO/President
Director

Allen Krantz, PhD
Director and Corporate Secretary

Jean Bellin
Director

Gary W Hayes, MD
Director

Kenneth C. Phillippe
CFO

Scientific Advisory Board:
Prof. Paul A. Wender
Stanford University

Prof. Stephen Hanessian
University of Montreal

Prof. Stephen G. Withers
University of British Columbia

Audit Committee:
Jean Bellin
Chair, Audit Committee

Allen Krantz, Ph.D.

Gary W, Hayes, MD

Compensation Committee:
Jean Bellin
Gary W, Hayes, MD

Corporate Advisory Board:
Paul Woodward
President – Conation Capital Corp.

David Webb, Ph.D.
Adjunct Prof. – The Scripps Research Institute

John R. Garrett, Ph.D.
co-Ceo – Glycosyn LLC

Auditor:
Dale Matheson
Carr-Hilton LaBonte LLP

Investor Contact:
Babak Pedram
Investor Relations
Virtus Advisory Group Inc.

Phone: 416-644-5081
Email: bpedram@virtusadvisory.com